Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)

Age

18–70

Sex

ALL

Healthy volunteers

Not accepted

\-
1.Age: 18-70 Years (Contains boundary values 18 and 70);
2.The newly diagnosed PTCL confirmed by histopathology is one of the following subtypes;
a) Angioimmunoblastic T-cell lymphoma (AITL); b) Follicular T helper cell lymphoma (T-FHCL); Including but not limited to the above two subtypes;
3.ECOG ≤ 3;
4.At least one measurable or evaluable tumor lesion according to the Lugano-2014 standard;
5.Expected survival ≥ 3 months;
6.Subjects fully understand and voluntarily participate in this study and sign informed consent;

\-
1.Subjects who have previously received systemic treatment for lymphoma or currently undergoing anticancer treatment;
2.Subjects with central nervous system (CNS) lymphoma or lymphoma involving CNS;
3.Significant active heart disease within the past 6 months, including: New York Heart Association (NYHA) Class III/IV congestive heart failure unstable angina pectoris or angina requiring surgical or medication intervention, and/or myocardial infarction;
4.Uncontrolled systemic fungal, bacterial, or viral infections (defined as persistent signs/symptoms related to infection that have not improved despite the use of appropriate antibiotics, antiviral therapy, and/or other treatments);
5.Human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection and history of severe skin reaction;
6.Subjects with any other active malignant tumor at the time of screening, except for adequately treated cervical Carcinoma in situ or breast cancer Carcinoma in situ, skin Basal-cell carcinoma or local skin squamous cell carcinoma;
7.Pregnant women, lactating women, patients who refused to take effective contraceptive measures during the study;
8.Any serious uncontrolled systemic disease;
9.increasing the risk of the subject or interfering with the test results determined by the investigator;